Novo Nordisk A/S Class B
NONOF
Market Cap$250.04B
Close$
Earnings Call Q2 2025
August 6, 2025 - AI Summary
Sales Growth and Profitability: Novo Nordisk reported an 18% sales growth and a 29% operating profit growth for the first half of 2025. However, the company lowered its full-year sales growth outlook to 8-14% (down from previous expectations), primarily due to reduced forecasts for Wegovy in the U.S. obesity market and Ozempic in the GLP-1 diabetes market.
Forecast and Updated Guidance: The updated financial outlook for 2025 indicates a sales growth of 8-14% and an operating profit growth of 10-16% at constant exchange rates. This is 3-5 percentage points lower than previously communicated figures due to expectations of slower growth in the second half of 2025.
Challenges with Wegovy and Compounding: Wegovy's sales growth has been affected by the continued existence of compounded GLP-1 medications, impacting its market penetration. Approximately 1 million patients are estimated to be on compounded GLP-1s, which Novo Nordisk is actively challenging to protect patient safety and compliance.
Exclusive for Stockcircle Pro members
Sign up
$91.58
67.1% upside
Current Fair Value
67.1% upsideUndervalued by 67.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $250.04 Billion |
|---|---|
| Enterprise Value | $347.80 Billion |
| Dividend Yield | $1.73 (3.25%) |
| Earnings per Share | $22.68 |
| Beta | 0.27 |
| Outstanding Shares | 4,446,812,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.37 |
|---|---|
| PEG | 44.63 |
| Price to Sales | 0.78 |
| Price to Book Ratio | 1.48 |
| Enterprise Value to Revenue | 1.11 |
| Enterprise Value to EBIT | 2.3 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Novo Nordisk A/S
CEO: Lars Fruergaard J?rgensen Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The...